These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 31917122)

  • 1. S-1 and Oxaliplatin Versus Tegafur-uracil and Leucovorin as Postoperative Adjuvant Chemotherapy in Patients With High-risk Stage III Colon Cancer (ACTS-CC 02): A Randomized, Open-label, Multicenter, Phase III Superiority Trial.
    Sunami E; Kusumoto T; Ota M; Sakamoto Y; Yoshida K; Tomita N; Maeda A; Teshima J; Okabe M; Tanaka C; Yamauchi J; Itabashi M; Kotake K; Takahashi K; Baba H; Boku N; Aiba K; Ishiguro M; Morita S; Takenaka N; Okude R; Sugihara K
    Clin Colorectal Cancer; 2020 Mar; 19(1):22-31.e6. PubMed ID: 31917122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. S-1 and oxaliplatin versus tegafur-uracil and leucovorin as post-operative adjuvant chemotherapy in patients with high-risk stage III colon cancer: updated 5-year survival of the phase III ACTS-CC 02 trial.
    Watanabe J; Sasaki S; Kusumoto T; Sakamoto Y; Yoshida K; Tomita N; Maeda A; Teshima J; Yokota M; Tanaka C; Yamauchi J; Uetake H; Itabashi M; Takahashi K; Baba H; Kotake K; Boku N; Aiba K; Morita S; Takenaka N; Sugihara K
    ESMO Open; 2021 Apr; 6(2):100077. PubMed ID: 33714860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Planned Safety Analysis of the ACTS-CC 02 Trial: A Randomized Phase III Trial of S-1 With Oxaliplatin Versus Tegafur and Uracil With Leucovorin as Adjuvant Chemotherapy for High-Risk Stage III Colon Cancer.
    Kusumoto T; Sunami E; Ota M; Yoshida K; Sakamoto Y; Tomita N; Maeda A; Mochizuki I; Okabe M; Kunieda K; Yamauchi J; Itabashi M; Kotake K; Takahashi K; Baba H; Boku N; Aiba K; Ishiguro M; Morita S; Sugihara K
    Clin Colorectal Cancer; 2018 Jun; 17(2):e153-e161. PubMed ID: 29249584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S-1 as adjuvant chemotherapy for stage III colon cancer: a randomized phase III study (ACTS-CC trial).
    Yoshida M; Ishiguro M; Ikejiri K; Mochizuki I; Nakamoto Y; Kinugasa Y; Takagane A; Endo T; Shinozaki H; Takii Y; Mochizuki H; Kotake K; Kameoka S; Takahashi K; Watanabe T; Watanabe M; Boku N; Tomita N; Nakatani E; Sugihara K;
    Ann Oncol; 2014 Sep; 25(9):1743-1749. PubMed ID: 24942277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC).
    Oki E; Murata A; Yoshida K; Maeda K; Ikejiri K; Munemoto Y; Sasaki K; Matsuda C; Kotake M; Suenaga T; Matsuda H; Emi Y; Kakeji Y; Baba H; Hamada C; Saji S; Maehara Y
    Ann Oncol; 2016 Jul; 27(7):1266-72. PubMed ID: 27056996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomised-controlled trial of 1-year adjuvant chemotherapy with oral tegafur-uracil versus surgery alone in stage II colon cancer: SACURA trial.
    Matsuda C; Ishiguro M; Teramukai S; Kajiwara Y; Fujii S; Kinugasa Y; Nakamoto Y; Kotake M; Sakamoto Y; Kurachi K; Maeda A; Komori K; Tomita N; Shimada Y; Takahashi K; Kotake K; Watanabe M; Mochizuki H; Nakagawa Y; Sugihara K;
    Eur J Cancer; 2018 Jun; 96():54-63. PubMed ID: 29677641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomised phase III trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage III colorectal cancer who have undergone Japanese D2/D3 lymph node dissection: final results of JCOG0205.
    Shimada Y; Hamaguchi T; Mizusawa J; Saito N; Kanemitsu Y; Takiguchi N; Ohue M; Kato T; Takii Y; Sato T; Tomita N; Yamaguchi S; Akaike M; Mishima H; Kubo Y; Nakamura K; Fukuda H; Moriya Y
    Eur J Cancer; 2014 Sep; 50(13):2231-40. PubMed ID: 24958736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase III trial of treatment duration for oral uracil and tegafur plus leucovorin as adjuvant chemotherapy for patients with stage IIB/III colon cancer: final results of JFMC33-0502.
    Sadahiro S; Tsuchiya T; Sasaki K; Kondo K; Katsumata K; Nishimura G; Kakeji Y; Baba H; Sato S; Koda K; Yamaguchi Y; Morita T; Matsuoka J; Usuki H; Hamada C; Kodaira S
    Ann Oncol; 2015 Nov; 26(11):2274-80. PubMed ID: 26347106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of UFT/LV and S-1 as adjuvant therapy for stage III colon cancer in phase III trial: ACTS-CC trial.
    Mochizuki I; Takiuchi H; Ikejiri K; Nakamoto Y; Kinugasa Y; Takagane A; Endo T; Shinozaki H; Takii Y; Takahashi Y; Mochizuki H; Kotake K; Kameoka S; Takahashi K; Watanabe T; Watanabe M; Boku N; Tomita N; Matsubara Y; Sugihara K
    Br J Cancer; 2012 Mar; 106(7):1268-73. PubMed ID: 22415232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective observational study of the efficacy of oral uracil and tegafur plus leucovorin for stage II colon cancer with risk factors for recurrence using propensity score matching (JFMC46-1201).
    Sadahiro S; Sakamoto K; Tsuchiya T; Takahashi T; Ohge H; Sato T; Kondo K; Ogata Y; Baba H; Itabashi M; Ikeda M; Hamada M; Maeda K; Masuko H; Takahashi K; Sakamoto J; Kusano M; Hyodo I; Taguri M; Morita S
    BMC Cancer; 2022 Feb; 22(1):170. PubMed ID: 35168560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase III trial comparing UFT + PSK to UFT + LV in stage IIB, III colorectal cancer (MCSGO-CCTG).
    Miyake Y; Nishimura J; Kato T; Ikeda M; Tsujie M; Hata T; Takemasa I; Mizushima T; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M;
    Surg Today; 2018 Jan; 48(1):66-72. PubMed ID: 28634730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
    Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
    Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized phase II study of tegafur-uracil/leucovorin versus tegafur-uracil/leucovorin plus oxaliplatin after curative resection of high-risk stage II/III colorectal cancer (SOAC-1101 trial).
    Kosugi C; Koda K; Takiguchi N; Takaishi S; Miyauchi H; Hirayama N; Nomura Y; Kondo E; Kawasaki Y; Ozawa Y; Matsubara H
    Int J Colorectal Dis; 2021 Aug; 36(8):1739-1749. PubMed ID: 33715077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of oral tegafur-uracil as maintenance therapy following intravenous 5-fluorouracil chemotherapy in stage III colon cancer.
    Hong KD; Lee SI; Moon HY
    Hepatogastroenterology; 2012; 59(113):104-7. PubMed ID: 22251527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Final analyses of the prospective controlled trial on the efficacy of uracil and tegafur/leucovorin as an adjuvant treatment for stage II colon cancer with risk factors for recurrence using propensity score-based methods (JFMC46-1201).
    Ogata Y; Sadahiro S; Sakamoto K; Tsuchiya T; Takahashi T; Ohge H; Sato T; Kondo K; Baba H; Itabashi M; Ikeda M; Hamada M; Maeda K; Masuko H; Takahashi K; Kusano M; Hyodo I; Sakamoto J; Taguri M; Morita S
    Int J Clin Oncol; 2024 Sep; 29(9):1284-1292. PubMed ID: 38833114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and feasibility of S-1 plus oxaliplatin (C-SOX) for treating patients with stage III colon cancer (KSCC1303): final analysis of 3-year disease-free survival.
    Ando K; Emi Y; Miyanari N; Tsuji A; Sakai K; Sawai T; Imamura H; Mori S; Tokunaga S; Oki E; Saeki H; Kakeji Y; Akagi Y; Baba H; Maehara Y; Mori M;
    Int J Clin Oncol; 2020 Jun; 25(6):1115-1122. PubMed ID: 32189156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06.
    Lembersky BC; Wieand HS; Petrelli NJ; O'Connell MJ; Colangelo LH; Smith RE; Seay TE; Giguere JK; Marshall ME; Jacobs AD; Colman LK; Soran A; Yothers G; Wolmark N
    J Clin Oncol; 2006 May; 24(13):2059-64. PubMed ID: 16648506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial.
    Zhang X; Liang H; Li Z; Xue Y; Wang Y; Zhou Z; Yu J; Bu Z; Chen L; Du Y; Wang X; Wu A; Li G; Su X; Xiao G; Cui M; Wu D; Chen L; Wu X; Zhou Y; Zhang L; Dang C; He Y; Zhang Z; Sun Y; Li Y; Chen H; Bai Y; Qi C; Yu P; Zhu G; Suo J; Jia B; Li L; Huang C; Li F; Ye Y; Xu H; Wang X; Yuan Y; E JY; Ying X; Yao C; Shen L; Ji J;
    Lancet Oncol; 2021 Aug; 22(8):1081-1092. PubMed ID: 34252374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maintenance tegafur-uracil versus observation following an adjuvant oxaliplatin-based regimen in patients with stage III colon cancer after radical resection: study protocol for a randomized controlled trial.
    Yeh YS; Tsai HL; Huang CW; Wei PL; Sung YC; Tang HC; Wang JY
    Trials; 2017 Apr; 18(1):191. PubMed ID: 28441966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal schedule of adjuvant chemotherapy with S-1 for stage III colon cancer: study protocol for a randomized controlled trial.
    Yoshimura K; Uehara K; Tojima Y; Kawai S; Mokuno Y; Maeda A; Kyokane T; Kobayashi S; Yoshioka Y; Nagino M
    Trials; 2013 Jan; 14():17. PubMed ID: 23320901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.